Analysts Set Pulmonx Corporation (NASDAQ:LUNG) Target Price at $6.81

Shares of Pulmonx Corporation (NASDAQ:LUNG) have been given an average rating of “Hold” by the ten research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $6.8071.

A number of research analysts have issued reports on LUNG shares. D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of Pulmonx in a research note on Thursday, November 13th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday. Finally, Lake Street Capital cut their target price on Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th.

Pulmonx Trading Down 3.2%

Shares of NASDAQ LUNG opened at $1.79 on Thursday. Pulmonx has a 12-month low of $1.31 and a 12-month high of $9.37. The company has a market cap of $73.84 million, a price-to-earnings ratio of -1.27 and a beta of 0.10. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62. The stock’s 50 day simple moving average is $2.04 and its 200 day simple moving average is $1.95.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. The firm had revenue of $21.50 million for the quarter, compared to analyst estimates of $20.78 million. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%. Equities research analysts expect that Pulmonx will post -1.55 EPS for the current year.

Institutional Investors Weigh In On Pulmonx

Several institutional investors have recently bought and sold shares of LUNG. FNY Investment Advisers LLC bought a new position in Pulmonx in the 3rd quarter valued at about $29,000. Regatta Capital Group LLC acquired a new stake in shares of Pulmonx in the 4th quarter worth approximately $30,000. Jain Global LLC bought a new position in shares of Pulmonx in the third quarter valued at approximately $30,000. Corton Capital Inc. acquired a new position in shares of Pulmonx during the second quarter valued at approximately $32,000. Finally, Perkins Capital Management Inc. increased its stake in shares of Pulmonx by 110.0% during the third quarter. Perkins Capital Management Inc. now owns 21,000 shares of the company’s stock valued at $34,000 after acquiring an additional 11,000 shares during the period. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.